Ventripoint Diagnostics Ltd (VPTDF) 0.0310 $VPTDF
Ventripoint Announces Development of New VMS(TM) Products and Enhanced Capabilities as Featured at ASE 2015
Marketwired - Thu Jun 25, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that a new platform design of the VMS(TM) workstation will be made available to select markets with complete availability expected in the 4th quarter of 2015. The new platform, branded VMS-Plus(TM), was the Company's featured product at the American Society of Echocardiography Scientific Session (ASE 2015) held in Boston last week.
VPT.VN: 0.045 (unch)
Ventripoint Receives Marketing Clearance from the FDA to Expand the Use of the VMS Heart Analysis System
Marketwired - Tue May 26, 7:31AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has received Marketing Clearance from the U.S. Food & Drug Administration ("FDA" for the expanded Indications for Use of its VMS(TM) product which states; "The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired".
VPT.VN: 0.045 (unch)
Latest Clinical Study Finds Ventripoint VMS(TM) Offers Consistent and Accurate Results Regardless of Examiner
Marketwired - Mon Apr 27, 7:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that a group led by Dr. Daniel Knight in London, United Kingdom, has demonstrated further the accuracy of Ventripoint's VMS(TM) heart analysis system.
VPT.VN: 0.045 (unch)
Ventripoint Announces Response to Interactive Review for Recent 510(k) Submission to FDA
Marketwired - Wed Apr 08, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has completed the first round of review concerning the most recent 510(k) submission to the U.S. Food & Drug Administration ("FDA". On March 26th, 2015, Ventripoint received a request for additional information via Interactive Review. The Company responded promptly and delivered the requested information to the FDA for evaluation.
VPT.VN: 0.045 (unch)
Ventripoint Announces Distribution Partner for Military and VA Medical Centers
Marketwired - Mon Mar 30, 7:34AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation" (TSX VENTURE: VPT) is pleased to announce that is has appointed PYP Enterprises LLC (PYP) to be the exclusive distributor to the US military hospitals including the VA hospitals.
VPT.VN: 0.045 (unch)
Ventripoint Announces Acceptance Notification From US-FDA of Recent 510(k) Submission
Marketwired - Fri Mar 27, 7:01AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT) is pleased to announce that it has received Acceptance Review Notification concerning the Company's recent 510(k) submission (see news release March 16, 2015) to the U.S. Food & Drug Administration ("US-FDA". The Notification confirms that the submission contains all of the necessary elements and information needed to proceed with the substantive review. A lead reviewer has been assigned and the substantive review has begun. The US-FDA guidelines mandate that the Company receive its first communication regarding the submission within 60 days, with closure of the submission expected to occur within 90 days.
VPT.VN: 0.045 (unch)
Ventripoint Announces Resignation of Director
Marketwired - Wed Mar 25, 6:26AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that Mr. Brad Harlow has resigned from the Board of Directors of the Company to focus on his duties as CEO of Cardiac Insight Inc. He is also continuing as President & CEO of PhysioSonics Inc. These companies, plus his work with CBC Partners LLC, a lending company, are eclipsing the time needed as a Director at Ventripoint. The Company wishes him success in the future and thanks him for his over 4 years of excellent service and dedication to governance of the Company.
VPT.VN: 0.045 (unch)
Ventripoint Applies to U.S. FDA to Expand Use of the VMS Heart Analysis System to all Types of Heart Disease
Marketwired - Mon Mar 16, 7:17AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has recently filed an additional submission for 510(k) clearance to the U.S. Food & Drug Administration (FDA).
VPT.VN: 0.045 (unch)
Ventripoint Announces Completion of Initial Establishment Inspection by FDA
Marketwired - Tue Jan 13, 3:00PM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has completed an initial Establishment Inspection by the U.S. Food and Drug Administration (FDA) on January 8, 2015. This initial Establishment Inspection following 510(k) clearance of the Ventripoint Medical System in March, 2014, was started on December 29, 2014 at the Company's Bellevue, Washington location. It was a pre-announced Good Manufacturing Practices (GMP) facility inspection. "This was a very detailed inspection of our Quality System as it relates to Federal Regulations," stated Jeff Jellum, Director of Operations. The inspection reported only two observations as noted on FDA Form 483. "While we strive for perfection, we are pleased to have only two minor items that are easily addressed following our first FDA inspection."
VPT.VN: 0.045 (unch)
Ventripoint Announces Development of New VMS(TM) Products and Enhanced Capabilities as Featured at ASE 2015
Marketwired - Thu Jun 25, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that a new platform design of the VMS(TM) workstation will be made available to select markets with complete availability expected in the 4th quarter of 2015. The new platform, branded VMS-Plus(TM), was the Company's featured product at the American Society of Echocardiography Scientific Session (ASE 2015) held in Boston last week. VPT.VN: 0.045 (unch)
Ventripoint Receives Marketing Clearance from the FDA to Expand the Use of the VMS Heart Analysis System
Marketwired - Tue May 26, 7:31AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has received Marketing Clearance from the U.S. Food & Drug Administration ("FDA" for the expanded Indications for Use of its VMS(TM) product which states; "The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired". VPT.VN: 0.045 (unch)
Latest Clinical Study Finds Ventripoint VMS(TM) Offers Consistent and Accurate Results Regardless of Examiner
Marketwired - Mon Apr 27, 7:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that a group led by Dr. Daniel Knight in London, United Kingdom, has demonstrated further the accuracy of Ventripoint's VMS(TM) heart analysis system. VPT.VN: 0.045 (unch)
Ventripoint Announces Response to Interactive Review for Recent 510(k) Submission to FDA
Marketwired - Wed Apr 08, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has completed the first round of review concerning the most recent 510(k) submission to the U.S. Food & Drug Administration ("FDA". On March 26th, 2015, Ventripoint received a request for additional information via Interactive Review. The Company responded promptly and delivered the requested information to the FDA for evaluation. VPT.VN: 0.045 (unch)
Ventripoint Announces Distribution Partner for Military and VA Medical Centers
Marketwired - Mon Mar 30, 7:34AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation"
(TSX VENTURE: VPT) is pleased to announce that is has appointed PYP Enterprises LLC (PYP) to be the exclusive distributor to the US military hospitals including the VA hospitals. VPT.VN: 0.045 (unch)
Ventripoint Announces Acceptance Notification From US-FDA of Recent 510(k) Submission
Marketwired - Fri Mar 27, 7:01AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"
(TSX VENTURE: VPT) is pleased to announce that it has received Acceptance Review Notification concerning the Company's recent 510(k) submission (see news release March 16, 2015) to the U.S. Food & Drug Administration ("US-FDA". The Notification confirms that the submission contains all of the necessary elements and information needed to proceed with the substantive review. A lead reviewer has been assigned and the substantive review has begun. The US-FDA guidelines mandate that the Company receive its first communication regarding the submission within 60 days, with closure of the submission expected to occur within 90 days. VPT.VN: 0.045 (unch)
Ventripoint Announces Resignation of Director
Marketwired - Wed Mar 25, 6:26AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that Mr. Brad Harlow has resigned from the Board of Directors of the Company to focus on his duties as CEO of Cardiac Insight Inc. He is also continuing as President & CEO of PhysioSonics Inc. These companies, plus his work with CBC Partners LLC, a lending company, are eclipsing the time needed as a Director at Ventripoint. The Company wishes him success in the future and thanks him for his over 4 years of excellent service and dedication to governance of the Company. VPT.VN: 0.045 (unch)
Ventripoint Applies to U.S. FDA to Expand Use of the VMS Heart Analysis System to all Types of Heart Disease
Marketwired - Mon Mar 16, 7:17AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has recently filed an additional submission for 510(k) clearance to the U.S. Food & Drug Administration (FDA). VPT.VN: 0.045 (unch)
Ventripoint Announces Completion of Initial Establishment Inspection by FDA
Marketwired - Tue Jan 13, 3:00PM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has completed an initial Establishment Inspection by the U.S. Food and Drug Administration (FDA) on January 8, 2015. This initial Establishment Inspection following 510(k) clearance of the Ventripoint Medical System in March, 2014, was started on December 29, 2014 at the Company's Bellevue, Washington location. It was a pre-announced Good Manufacturing Practices (GMP) facility inspection. "This was a very detailed inspection of our Quality System as it relates to Federal Regulations," stated Jeff Jellum, Director of Operations. The inspection reported only two observations as noted on FDA Form 483. "While we strive for perfection, we are pleased to have only two minor items that are easily addressed following our first FDA inspection." VPT.VN: 0.045 (unch)
